Click to Share
 

Personalized Medicine Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By Arrowhead Publishers & Conferences
Researchers at the University of California, San Diego have discovered proof of concept in determining whether a drug will produce adverse side effects based on assessing blood samples.
By Genelex
Recently, Genelex responded to requests by various stakeholders in the personalized and precision medicine industry by creating High Risk PGx Drug Charts, which are available on the YouScript software.
By Sage Bionetworks
In the midst of several colliding perspectives on personal data sharing from both patients and researchers, it is challenging to comprehend how clinical study designs should be conducted to benefit both stakeholders.
By CytoTest Inc.
CytoTest Inc., the Uniformed Services University of the Health Sciences (USU), and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) announced today that they signed a Cooperative Research and Development Agreem
By New Amsterdam Genomics
October 2nd, 2014, (New York, NY) - New Amsterdam Genomics and Prodigo Solutions today announced a partnership that will allow Prodigo Solutions to offer NAG’s revolutionary Genomic sequencing and analysis platform through their digital catalogue,...
12372911
By Woodland Pharmaceuticals
Woodland is partnering with PreThera Research of Quebec, Canada to create a "Living Legacy" Viable Tumor Bank to study cancer recurrence and drug resistance with funding from the government. Woodland's new labs will be the center of this activity.
By Paradigm
Collaboration will enhance clinical trials by identifying proteomic and other predictors of response to targeted cancer therapies.
By Xhale, Inc
The Board of Directors of Xhale, Inc. today announced the appointment of Nauman (Nick) Toor as a board member of Xhale, Inc. Mr.
12331211
By GATC Biotech AG
Constance, Germany – GATC Biotech launches its InView™ 2-weeks Exome service and enhanced, customised epigenetic support for its more than 10,000 clients.
12324660
By GATC Biotech
Partners in personalised medicine – jointly individualising cancer therapy
By Arrowhead Publishers
Dr. Daniel Grosu of Illumina will present his perspective on the issues surrounding personalized medicine at the 5th Annual Personalized medicine conference in Boston, MA, October 21-22, 2013, an official satellite event to the American Society of Human..
By Proove Biosciences
Five new doctors and leading pain management clinics in Washington State will begin utilizing Proove Biosciences’ Genetic Testing
By Proove Biosciences
Proove Biosciences’ Vice President of Research and Development, Ben Arthur, Exhibited Proove’s Capacity to Commercialize Genetic Technology in Optimizing Pain Treatments
By Arrowhead Publishers
Matthew Zubiller, Decision Management Executive at Mckesson will discuss Understanding the Value of Advanced Diagnostics: Aligning Labs, Clinicians and Payers to Make Better Decisions at the 5th Annual Personalized Medicine Conference
12131833
By Mercury Healthcare International
Concierge Medicine Handbook author, Maria Todd invited to write an article in ThePatient.com, a new German lifestyle magazine about being a concierge medicine patient - how and why she chose her doctor, and what its like to be a patient.
By IGDRASOL
IGDRASOL will present updates on Cynviloq™, its late clinical stage paclitaxel nanoparticle formulation.
12094030
By IGDRASOL
Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers.
12078760
By IGDRASOL
IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI.
12062970
By IGDRASOL
IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA.
12049153
By IGDRASOL
IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing.

All Press Releases

By Arrowhead Publishers & Conferences
Researchers at the University of California, San Diego have discovered proof of concept in determining whether a drug will produce adverse side effects based on assessing blood samples.
By Genelex
Recently, Genelex responded to requests by various stakeholders in the personalized and precision medicine industry by creating High Risk PGx Drug Charts, which are available on the YouScript software.
By Sage Bionetworks
In the midst of several colliding perspectives on personal data sharing from both patients and researchers, it is challenging to comprehend how clinical study designs should be conducted to benefit both stakeholders.
By CytoTest Inc.
CytoTest Inc., the Uniformed Services University of the Health Sciences (USU), and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) announced today that they signed a Cooperative Research and Development Agreem
By New Amsterdam Genomics
October 2nd, 2014, (New York, NY) - New Amsterdam Genomics and Prodigo Solutions today announced a partnership that will allow Prodigo Solutions to offer NAG’s revolutionary Genomic sequencing and analysis platform through their digital catalogue,...
12372911
By Woodland Pharmaceuticals
Woodland is partnering with PreThera Research of Quebec, Canada to create a "Living Legacy" Viable Tumor Bank to study cancer recurrence and drug resistance with funding from the government. Woodland's new labs will be the center of this activity.
By Paradigm
Collaboration will enhance clinical trials by identifying proteomic and other predictors of response to targeted cancer therapies.
By Xhale, Inc
The Board of Directors of Xhale, Inc. today announced the appointment of Nauman (Nick) Toor as a board member of Xhale, Inc. Mr.
By Pharmatech Inc.
Exciting new data acquisition will lead to impressive results for Pharmatech's biomarker database
12331211
By GATC Biotech AG
Constance, Germany – GATC Biotech launches its InView™ 2-weeks Exome service and enhanced, customised epigenetic support for its more than 10,000 clients.
12324660
By GATC Biotech
Partners in personalised medicine – jointly individualising cancer therapy
By FOIRMYS
When you open a 70-year old patient on the operating table and touch the aorta, the feeling may resemble touching an eggshell or sand paper.
By Arrowhead Publishers
Dr. Daniel Grosu of Illumina will present his perspective on the issues surrounding personalized medicine at the 5th Annual Personalized medicine conference in Boston, MA, October 21-22, 2013, an official satellite event to the American Society of Human..
By Proove Biosciences
Five new doctors and leading pain management clinics in Washington State will begin utilizing Proove Biosciences’ Genetic Testing
By Proove Biosciences
Proove Biosciences’ Vice President of Research and Development, Ben Arthur, Exhibited Proove’s Capacity to Commercialize Genetic Technology in Optimizing Pain Treatments
By Arrowhead Publishers
Matthew Zubiller, Decision Management Executive at Mckesson will discuss Understanding the Value of Advanced Diagnostics: Aligning Labs, Clinicians and Payers to Make Better Decisions at the 5th Annual Personalized Medicine Conference
By Proove Biosciences
During the April 27th, 2013 National Drug Take Back Day, 387 Pounds of Prescription Medication was Collected and Disposed
12131833
By Mercury Healthcare International
Concierge Medicine Handbook author, Maria Todd invited to write an article in ThePatient.com, a new German lifestyle magazine about being a concierge medicine patient - how and why she chose her doctor, and what its like to be a patient.
By Applied Spectral Imaging Inc.
Delivering a state-of-the-art integrated computerized analysis instrument and cell enrichment solution
By IGDRASOL
IGDRASOL will present updates on Cynviloq™, its late clinical stage paclitaxel nanoparticle formulation.
By Cypher Genomics
Cypher Genomics: Ahead of the Curve A San Diego Company is Poised to Lead the Genome Interpretation Industry SAN DIEGO, C.A., Mar.
12094030
By IGDRASOL
Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers.
12078760
By IGDRASOL
IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI.
12062970
By IGDRASOL
IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA.
12049153
By IGDRASOL
IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing.
12044119
By IGDRASOL
Personalization of paclitaxel therapy by combination of next generation nanoparticle paclitaxel and point-of-care therapeutic drug monitoring and biomarker testing.
By Cambridge Healthtech Institute
CHI’s 2nd Annual Point-of-Care Diagnostics Symposium, February 11-12, 2013, San Francisco, CA
12040014
By Bio-IT World
Next-Gen Technology | Big Data | Personalized Medicine | Bio-ITWorld.com
By Mary Ann Liebert, Inc., publishers
Many biotech observers maintain that the future of healthcare will largely be based on the field of personalized medicine, reports Genetic Engineering & Biotechnology News (GEN).
By Arrowhead Publishers & Conferences
Arrowhead Publishers & Conferences has just announced a new panel session to take place at their 4th Annual Personalized medicine Conference (Boston, MA, September 12-13, 2012) entitled: The Angel Investor & Venture Capital Perspective

Page:
Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share